InvestorsHub Logo
Followers 655
Posts 19047
Boards Moderated 3
Alias Born 07/03/2011

Re: frankyahoo post# 54

Wednesday, 06/29/2022 8:44:50 AM

Wednesday, June 29, 2022 8:44:50 AM

Post# of 162
NeuroSense Therapeutics reports completion of the "in-life" phase of its 90-day GLP Toxicology study successfully. All animals appeared normal, with no significant findings observed. In this study the components of PrimeC, celecoxib and ciprofloxacin, were administered to rodents at doses 4x the maximal clinical dose. The company will present the data obtained in this study to the FDA as part of PrimeC's drug development plan.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NRSN News